ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.551,43
0,12%
S&P 500
5.954,50
1,59%
Dow Jones
43.840,91
1,39%
Euro vs US Dollar
1,0375
-0,02%
Bitcoin
85.052,14
-1,14%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Amarin Corp PLC (AMRN)

  7. Amarin Corp PLC (AMRN) News

AMRN

Amarin (AMRN)

Amarin Corp PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AMRN
DatumZeitQuelleÜberschriftSymbolFirma
27/02/202515h00GlobeNewswire Inc.Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol LoweringNASDAQ:AMRNAmarin Corp PLC
25/02/202514h00GlobeNewswire Inc.Amarin Receives National Reimbursement for VAZKEPA® in AustriaNASDAQ:AMRNAmarin Corp PLC
19/02/202514h30GlobeNewswire Inc.Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025NASDAQ:AMRNAmarin Corp PLC
31/01/202522h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
31/01/202522h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
31/01/202522h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
10/01/202523h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
10/01/202523h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
10/01/202523h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
18/12/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
16/12/202413h00GlobeNewswire Inc.Amarin Receives National Reimbursement for VAZKEPA® in ItalyNASDAQ:AMRNAmarin Corp PLC
13/12/202415h00GlobeNewswire Inc.Amarin Appoints Peter Fishman Chief Financial OfficerNASDAQ:AMRNAmarin Corp PLC
22/11/202422h49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
11/11/202414h00GlobeNewswire Inc.Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) AnnualNASDAQ:AMRNAmarin Corp PLC
31/10/202421h42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
30/10/202421h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRNAmarin Corp PLC
30/10/202421h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
30/10/202421h05GlobeNewswire Inc.Amarin Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AMRNAmarin Corp PLC
01/10/202414h00GlobeNewswire Inc.Amarin Announces Two Upcoming Investor EventsNASDAQ:AMRNAmarin Corp PLC
09/09/202413h30GlobeNewswire Inc.Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual EuropeNASDAQ:AMRNAmarin Corp PLC
22/08/202414h30GlobeNewswire Inc.Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressNASDAQ:AMRNAmarin Corp PLC
05/08/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
01/08/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
01/08/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
31/07/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
31/07/202413h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRNAmarin Corp PLC
31/07/202413h00GlobeNewswire Inc.Amarin Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AMRNAmarin Corp PLC
29/07/202423h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
17/07/202422h15GlobeNewswire Inc.Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in PortugalNASDAQ:AMRNAmarin Corp PLC
17/07/202414h00GlobeNewswire Inc.Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024NASDAQ:AMRNAmarin Corp PLC
 Showing the most relevant articles for your search:NASDAQ:AMRN

Kürzlich von Ihnen besucht

AMEX
XLE
Energy Select Sector SPDR
COIN
SOLUSD
Solana
TG
ALV
Allianz
COIN
XRPUSD
Ripple
TG
DTE
Deutsche Telekom
AMEX
XLV
Health Care Select Sector
NYSE
MRK
Merck
COIN
ETHUSD
Ethereum
TG
432
Arbor Metals
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
GOOGL
Alphabet
DBI
SDXP
SDAX
COIN
AVAXUSD
Avalanche
USOTC
BASFY
BASF (QX)
TG
RHM
Rheinmetall
FX
EURGBP
Euro vs Sterling
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten